Next Article in Journal
A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
Previous Article in Journal
Heterodimeric IL-15 in Cancer Immunotherapy
 
 
Article

Article Versions Notes

Cancers 2021, 13(4), 835; https://doi.org/10.3390/cancers13040835
Action Date Notes Link
article xml file uploaded 17 February 2021 11:00 CET Original file -
article xml uploaded. 17 February 2021 11:00 CET Update https://www.mdpi.com/2072-6694/13/4/835/xml
article pdf uploaded. 17 February 2021 11:00 CET Version of Record https://www.mdpi.com/2072-6694/13/4/835/pdf
article supplementary file uploaded. 17 February 2021 11:00 CET - https://www.mdpi.com/2072-6694/13/4/835#supplementary
article html file updated 17 February 2021 11:02 CET Original file -
article html file updated 19 February 2021 13:42 CET Update -
article html file updated 25 July 2022 03:48 CEST Update https://www.mdpi.com/2072-6694/13/4/835/html
Back to TopTop